1,916 material Form 8-K filings that 1,609 companies we cover made with the SEC in July 2026, each read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). All of them were written later, when past filings were added: a selection, not every 8-K of the month (see the note below).
Lemonade's board named Senior Vice President Finance Nick Stead as chief financial officer, effective January 1, 2027, replacing Tim Bixby, who will move to a Class III board seat on the same date. The change is a planned leadership succession, and compensation terms for both men are still to be disclosed in a later amendment.
Board approved the changes on July 27, 2026; Bixby moves from CFO to Class III director effective January 1, 2027
Nick Stead, 33, currently SVP Finance, will become CFO and principal financial and accounting officer effective January 1, 2027
Stead joined Lemonade in December 2019 and was promoted to SVP Finance in July 2024
Compensation for Stead and any transition agreement with Bixby will be disclosed in a future 8-K amendment
Westin Acquisition Corp, a Cayman Islands special purpose acquisition company, signed a business combination agreement on July 22, 2026 with First Choice Healthcare Solutions, Inc. Under the deal, Westin will redomicile to Nevada as Wellgevity 360, Inc. and First Choice will become a wholly owned subsidiary, with the company valued at an equity value of up to approximately $650 million. The transaction requires shareholder and SEC approvals and is expected to close in the fourth quarter of 2026, so shareholders will face a vote and potential dilution from new shares issued.
Business combination agreement signed July 22, 2026; Westin to redomicile to Nevada as Wellgevity 360, Inc.
Equity value of up to approximately $650 million, paid in PubCo common stock
PIPE investors may buy up to $10,000,000 of PubCo preferred stock, with no subscription agreements executed yet
Transaction expected to close in the fourth quarter of 2026, subject to shareholder and SEC approvals
Axiom Intelligence Acquisition Corp 1, a special purpose acquisition company, issued an unsecured, non-interest-bearing promissory note of up to $1,000,000 to its sponsor on July 27, 2026, to fund working capital. The note can be converted at the sponsor's option into units priced at $10.00 each, which would add shares and rights to the company's share count; for shareholders, this is a routine sponsor funding arrangement with potential dilution if converted.
Note principal of up to $1,000,000 issued July 27, 2026 to Axiom Intelligence Holdings 1 LLC, the sponsor
Note bears no interest and matures on the earlier of an initial business combination closing or liquidation
Sponsor may convert outstanding amounts into units at $10.00 per unit; each unit holds one Class A ordinary share and one right to receive one-tenth of a share
On July 24, 2026, Cboe entered into a Third Amended and Restated Credit Agreement with Bank of America as administrative agent, providing a senior unsecured $400 million five-year revolving credit facility that matures July 24, 2031. The company may increase commitments by up to $200 million, to $600 million total, subject to lender agreement, and the facility replaces the prior agreement dated February 25, 2022.
Facility size: $400 million senior unsecured revolving credit, with a $25 million swing line sub-facility
Potential expansion: up to $200 million additional commitments, for a total of $600 million, subject to lender agreement
Maturity: July 24, 2031, unless terminated earlier
Financial covenants: minimum interest coverage ratio of 4.00 to 1.00 and maximum leverage ratio of 3.50 to 1.00, with step-ups to 4.25 and 4.00 under specified conditions
Market Technology Acquisition Corp closed its initial public offering of 20,500,000 units on July 27, 2026, generating gross proceeds of $205 million, including a partial exercise of the underwriters' over-allotment option. The company is a blank check company (SPAC) with no business combination announced in this filing, and funds in the trust account can generally not be released until a business combination is completed or shareholders redeem their shares.
IPO of 20,500,000 units at $10.00 per unit, including 500,000 units from the partial over-allotment exercise, for gross proceeds of $205,000,000
Concurrent private placement of 712,500 units for $7,125,000, bought by the Sponsor (452,500 units) and BTIG, LLC (260,000 units)
$206,500,000 placed in a U.S.-based trust account, equal to $10.05 per unit; the company has 21 months from the IPO closing to complete an initial business combination
Gary Greenberg appointed to the board on July 23, 2026, and to the Audit Committee chair role
Freshworks announced that Ryan Manning has been appointed Chief Product and Technology Officer, effective August 10, 2026. He will oversee the company's global product and engineering functions, a senior role covering core product development.
Ryan Manning appointed Chief Product and Technology Officer
Effective date: August 10, 2026
Will oversee global product and engineering functions
Announced July 28, 2026 in a filing under Item 8.01 (Other Events)
Ashland Inc. appointed Peter Thomas and Allen Spizzo as independent directors on July 27, 2026, and entered into a Cooperation Agreement with stockholder Ancora Holdings Group, LLC. The company also formed a Capital Allocation Advisory Committee to make recommendations to the Board on capital allocation strategy. The filing does not include financial results, so it gives shareholders governance changes rather than a measure of operating performance.
Peter Thomas and Allen Spizzo appointed as independent directors effective July 27, 2026; Board temporarily expands to 11 members, then reduces to 10 at the 2027 Annual Meeting
Cooperation Agreement with Ancora includes voting commitments and standstill obligations, and remains in effect through a Standstill Period tied to the 2028 Annual Meeting notice deadline
Capital Allocation Advisory Committee chaired by Scott A. Tozier, with Thomas as Vice Chair and Guillermo Novo as non-voting member
On July 28, 2026, SCE Recovery Funding LLC issued $1,953,948,000 of Senior Secured Recovery Bonds, Series 2026-A, under a prospectus dated July 21, 2026. The proceeds go to Southern California Edison, net of certain issuance costs, in exchange for recovery property created under a California Public Utilities Commission financing order. The filing does not disclose the bonds' interest rate or maturity.
Bonds totaling $1,953,948,000 issued July 28, 2026, under an indenture with The Bank of New York Mellon Trust Company as trustee.
Recovery property was created under a CPUC financing order issued May 23, 2026 (Decision No. 26-05-006), and sold to the issuer at closing.
Counsel Norton Rose Fulbright opined that bondholders would likely be able to challenge future state legislation that impairs the bonds, absent a significant public purpose justification by the state.
HF Sinclair said its Executive Vice President and General Counsel, Eric Nitcher, will retire from his executive officer role effective July 31, 2026. He is expected to stay on as an employee through the end of 2026 to support an orderly transition and serve in an advisory capacity, and the company has not yet named a successor. The filing states the retirement was not the result of any disagreement with the company or its Board.
Eric Nitcher, Executive Vice President and General Counsel, notified the Board on July 27, 2026 of his retirement.
Retirement from executive officer role is effective July 31, 2026.
Nitcher is expected to remain an employee through the end of 2026 in an advisory capacity.
A successor will be named at a later date; the filing states no disagreement led to the decision.
Wendy's filed an 8-K disclosing a one-time restricted stock unit award with a grant date fair value of $500,000 for E.J. Wunsch, President, International. The compensation committee approved it on July 22, 2026, following the appointment of Robert D. Wright as CEO, and the company says it aims to maintain continuity and recognize the International business.
Award: one-time restricted stock unit grant with a grant date fair value of $500,000 to E.J. Wunsch
Approved by the Compensation and Human Capital Committee on July 22, 2026; effective grant date August 11, 2026
Vests in substantially equal installments on each of the first two anniversaries of grant, subject to continued employment
Follows the appointment of Robert D. Wright as President and CEO
Verisk Analytics said its Executive Vice President and Chief Information Officer, Nick Daffan, will no longer hold that role effective August 3, 2026, following a determination made on July 27, 2026. Daffan will serve as Strategic Advisor through the end of 2026, and Chief Technology Officer Jeff Negrete will serve as interim Chief Information Officer in addition to his current role. The filing does not disclose any financial results or guidance changes.
Nick Daffan's CIO role ends effective August 3, 2026; he becomes Strategic Advisor through the end of 2026
Jeff Negrete, current Chief Technology Officer, will serve as interim Chief Information Officer
The determination was made on July 27, 2026
Separation terms follow Appendix A of the Senior Executive Severance Benefits Plan, as disclosed in an April 5, 2022 Form 8-K
Diodes Incorporated's Board elected Evan Yu, a former Diodes senior vice president who retired in January 2023, as an independent director effective August 1, 2026. The filing describes his prior roles at the company and in the semiconductor industry, and states that he qualifies as independent under Nasdaq and Rule 10A-3 standards.
Board elected Evan Yu on July 27, 2026, effective August 1, 2026
Yu previously served as Senior Vice President, Worldwide Power Products, joining the company in 2008 and retiring in January 2023
Before Diodes, Yu was CEO of Commit Inc. and worked at Texas Instruments for 15 years
Company issued a press release dated July 28, 2026 (Exhibit 99.1) announcing the appointment
Southern Cross Acquisition I Corp., a blank check company, completed its initial public offering of 11,500,000 units at $10.00 per unit on July 22, 2026, for gross proceeds of $115,000,000. The full $115,000,000 was placed in a trust account for public shareholders, and the company must complete a business combination within 12 months or redeem public shares. The company's auditor included a going concern warning, stating that substantial doubt exists about its ability to continue.
11,500,000 units sold at $10.00 each on July 22, 2026, including 1,500,000 units from the full exercise of the underwriters' over-allotment option
Sponsor bought 239,300 private units at $10.00 each for gross proceeds of $2,393,000
$115,000,000 placed in a trust account maintained by Continental Stock Transfer & Trust Company
Auditor TAAD, LLP cited substantial doubt about going concern due to the 12-month deadline to complete a business combination
Cadiz's subsidiary Fenner Gap Mutual Water Company signed two construction manager at risk agreements on July 27, 2026, with guaranteed maximum prices totaling about $273.8 million for the Northern Pipeline. The company estimates total construction capital expenditures to place the pipeline into service at about $403.3 million, so the agreements cover most of the estimated cost and set a defined budget for the Mojave Groundwater Bank financing.
Lyles Agreement: guaranteed maximum price of about $218.9 million for pump-station facilities, with 15% project contingency.
Bubalo Agreement: guaranteed maximum price of about $54.9 million for pipeline replacement, with 10% project contingency.
Estimated total construction capital budget is about $403.3 million, including $129.5 million for owner-procured equipment and other items.
Construction starts after notices to proceed and financing and permitting conditions are met; the agreements assume a September 2026 notice to proceed.
Haemonetics' board elected Martin Madaus, a Carlyle Group Senior Operating Executive, as a director effective July 24, 2026. At the same meeting, shareholders re-elected eight directors, approved an advisory say-on-pay vote, ratified Ernst & Young LLP as auditor, and approved amended 2019 Long-Term Incentive Compensation and 2007 Employee Stock Purchase Plans. The plan changes authorize 4,680,000 additional shares under the incentive plan and extend both plans through 2036.
Martin Madaus elected director effective July 24, 2026; expected to join the Audit Committee and Governance and Compliance Committee
Non-employee director annual equity award with an approximate value of $200,000
Shareholders approved the incentive plan amendment, which authorizes 4,680,000 additional shares, with 37,730,923 votes for and 2,055,726 against
Ellen Zane, Christopher Simon and six other nominees re-elected for one-year terms expiring in 2027
AT&T completed its previously announced purchase of wireless spectrum licenses from EchoStar for approximately $23 billion on July 28, 2026. The company drew $14.5 billion across two term loans to help fund the purchase, and it reiterated its second-quarter 2026 financial outlook and capital allocation plan.
Purchase price of approximately $23 billion in cash for 600 MHz and 3.45 GHz band licenses, closed July 28, 2026
Term loan draws: $11.5 billion on a two-year facility and $3.0 billion on a 364-day facility, under a $17.5 billion Delayed Draw Term Loan Credit Agreement with Bank of America, N.A. as agent
AT&T reiterated the financial outlook and capital allocation plan from its second-quarter 2026 earnings release
Oklo Inc. said its Board appointed five individuals as executive officers effective July 27, 2026, including Alexandra Renner as Chief Product Officer and Vivek Narayanadas as General Counsel and Corporate Secretary. The filing states no new compensation arrangements or equity awards were granted to the appointees, and it does not describe any financial results or outlook.
Board appointed five executive officers on July 22, 2026, effective July 27, 2026
Alexandra Renner named Chief Product Officer; she has served in that role since May 2024
Michael Dixon named Vice President of Accounting and Controller and Principal Accounting Officer, joining from National Grid USA
No new compensation plans or equity awards were granted to the appointees
Welltower entered a new equity distribution agreement allowing it to sell up to $7.5 billion of common stock through sales agents and forward sale agreements, terminating its October 28, 2025 agreement. The filing also registers resale of up to 261,753 shares issued for a recent lease amendment. Because new share sales can dilute existing shareholders, the program matters to current holders, though the filing does not state how much stock has been or will be sold.
New equity distribution agreement dated July 28, 2026 covers up to $7,500,000,000 of common stock (ATM Shares)
Prior equity distribution agreement dated October 28, 2025 was terminated on July 28, 2026
Company may use forward sale agreements; it would receive no proceeds from borrowed-share sales by forward sellers
Resale prospectus supplement covers up to 261,753 shares issued as consideration for a recent lease amendment
Kennametal's Board said Chairman William Lambert will retire from the Board, including his Chairman role, at the conclusion of the October 27, 2026 annual shareholder meeting. The Board has appointed director Joseph Alvarado as his successor, effective October 28, 2026.
Lambert has served on the Board since March 2016 and as Chairman since October 2023.
Alvarado becomes incoming Chairman effective October 28, 2026.
Alvarado has been a director since 2018 and has chaired the Nominating/Corporate Governance Committee since 2023.
Alvarado is the retired Chairman, President and CEO of Commercial Metals Company.
Covista Inc. appointed Emily Chiu and Leslie Storms as independent directors effective August 17, 2026, and the board increased its size from ten to twelve members. The filing says both will stand for re-election at the 2026 annual meeting, and their committee assignments have not yet been set.
Appointments take effect August 17, 2026; board size rises from ten to twelve members.
Each director receives a $150,000 equity retainer of restricted stock units after the annual meeting and $85,000 in annual cash compensation paid quarterly.
After the appointments, 10 of Covista's 12 directors will be independent, according to the press release attached as Exhibit 99.1.
Zoom director William R. McDermott notified the company on July 27, 2026, that he is resigning from the board of directors, effective immediately. The filing states the resignation did not result from any disagreement with the company on its operations, policies or practices.
Resignation notified to the company on July 27, 2026, effective immediately
Director William R. McDermott resigned from the board of directors
Company states there were no disagreements on operations, policies or practices
Filing signed July 28, 2026 by Chief Legal Officer and Secretary Cheree McAlpine
On July 22, 2026, Adeia's compensation committee approved changes to severance agreements with its CFO Keith A. Jones, Chief Revenue Officer Dr. Mark Kokes, and Chief Legal Officer Kevin Tanji. The changes add equity vesting acceleration on a qualifying termination, and the amended agreements will be filed with the 10-Q for the quarter ended June 30, 2026, so the full terms are not yet public.
Committee approved changes on July 22, 2026 to prior severance agreements with three executives
Qualifying termination now accelerates vesting of equity awards scheduled to vest within 12 months of termination
Performance awards vest on actual performance for completed fiscal years and the greater of target or actual performance for other goals
Amended agreements to be filed as an exhibit to the Form 10-Q for the quarter ended June 30, 2026
CNH Industrial announced that Chief Technology Officer Jay Schroeder will retire effective January 1, 2027, and Agriculture Chief Commercial Officer Stefano Pampalone will retire effective September 1, 2026. Eric Shuman, currently Vice President, Precision Technology Product Management, will succeed Schroeder as CTO, while several other leaders take on expanded roles.
Jay Schroeder, Chief Technology Officer, retires effective January 1, 2027; both retirees are expected to stay on in advisory capacities
Eric Shuman, a more than 25-year company veteran, to be appointed Chief Technology Officer effective January 1, 2027
Stefano Pampalone, Agriculture Chief Commercial Officer, retires effective September 1, 2026; Chun Woytera, Carlo Materazzo and Markus Müller take expanded roles
Compensation arrangements for Mr. Shuman have not yet been finalized
BioNexus issued a press release describing progress toward commercializing the VitaGuard MRD platform in Southeast Asia following a working visit to Tongshu Gene facilities in China. The filing contains no financial results, new agreements or financial commitments, and it states that no definitive agreement has been executed for markets outside Southeast Asia.
Visit to Tongshu Gene facilities in Shanghai and Changzhou, China, led by Fidelion Chief Commercial Officer Dr. Muthu Meyyappan
Company continues to target initial deployment in select Southeast Asian medical hubs during 2026, subject to work and approvals
Work is underway in Malaysia and Singapore; Fidelion is in discussions with prospective partners outside Southeast Asia, with no definitive agreement executed
BioNexus owns approximately 15% of Fidelion Diagnostics
Conagra Brands completed a public offering of $500 million of 5.400% Senior Notes due August 1, 2031, on July 28, 2026. The filing adds $500 million of new debt, and the notes carry customary covenants and a change-of-control repurchase offer at 101% of principal.
Offering size: $500 million aggregate principal of 5.400% Senior Notes due August 1, 2031
Interest payments begin February 1, 2027; notes are senior unsecured obligations
Change of Control Triggering Event requires an offer to repurchase at 101% of principal plus accrued interest
Underwriters: BofA Securities, Goldman Sachs, Mizuho Securities and Wells Fargo Securities under a July 21, 2026 underwriting agreement
Leonardo DRS agreed to buy Raft LLC, a Virginia-based provider of open-architecture mission software and AI for data fusion, in an all-cash deal valued at $450 million. The company expects the deal to close in the fourth quarter of 2026 and to be accretive to Adjusted Diluted EPS in the first full year of ownership, subject to regulatory approvals.
Purchase price: $450 million all-cash, subject to customary post-closing adjustments
Expected tax benefit over 15 years with present value of approximately $50 million
Expected closing: fourth quarter of 2026; funding from cash on hand and revolving credit facility borrowings
Management will discuss the deal on the Q2 2026 earnings call on July 30, 2026
ZipRecruiter said Carmen Chan, formerly a Managing Director at Barclays, will become Chief Financial Officer effective August 17, 2026. David Travers, the company's president and interim CFO, will remain president but stop serving as interim CFO on that date. The filing discloses Ms. Chan's pay and equity grants, which matter to shareholders as a record of the new finance chief's incentives.
Annual base salary of $500,000, with a minimum 2026 annual bonus of $100,000
$200,000 onboarding bonus, payable in two installments 90 and 180 days after she starts
650,000 restricted stock units granted, of which 150,000 are performance-based and tied to a stock price metric
Effective date of August 17, 2026; David Travers continues as President
Relmada Therapeutics announced on July 28, 2026 that it appointed Bipin Dalmia, PhD, MBA, as Chief Business Officer, reporting to CEO Sergio Traversa. He will lead corporate strategy, commercial planning, and business development as the company advances NDV-01 toward late-stage development. The filing does not disclose compensation terms or financial figures for the appointment.
Appointment announced July 28, 2026; Dalmia reports directly to CEO Sergio Traversa
Responsibilities include corporate strategy, commercial planning, and business development
Previously Senior Vice President, Global Head of Portfolio Strategy & Business Development at Ferring Pharmaceuticals, with a 14-year tenure there
The filing does not disclose compensation or other financial terms of the appointment
Bicara Therapeutics appointed Jeremy Bender, Ph.D. and Christy Oliger to its Board of Directors, effective July 28, 2026, increasing the Board from nine to ten members. Director Kiran Mazumdar-Shaw resigned from the Board and its Nominating and Corporate Governance Committee on the same effective date, and the filing says her decision was not the result of any disagreement with the Company. The Board also formed a Launch Readiness Committee to advise management on commercialization strategy for ficerafusp alfa.
Jeremy Bender, Ph.D. appointed as a Class I director, serving until the 2028 annual meeting; joins the Audit Committee, replacing Carolyn Ng, Ph.D.
Christy Oliger appointed as a Class II director, serving until the 2029 annual meeting; joins the Nominating and Corporate Governance Committee.
Kiran Mazumdar-Shaw resigned from the Board and Nominating and Corporate Governance Committee, effective July 28, 2026.
Each non-employee director receives an initial option award of 38,950 shares of common stock; the new Launch Readiness Committee is chaired by Kate Haviland.
Valmont Industries said Mogens C. Bay, the board's chair, will retire from the Board at the end of the company's fiscal year on December 26, 2026. He informed the Board of his decision on July 27, 2026. Catherine J. Paglia, the current Vice Chair and Lead Independent Director, will succeed him as Board Chair upon his retirement. The filing does not include any financial results or guidance.
Mogens C. Bay informed the Board on July 27, 2026, of his decision to retire from the Board
Retirement takes effect at the end of the fiscal year, December 26, 2026
Catherine J. Paglia, Vice Chair and Lead Independent Director, will become Board Chair upon his retirement
On July 27, 2026, KIDZ AI's board raised the company's share repurchase program by 50%, from $2.0 million to up to $3.0 million of Class B common stock. The filing says repurchases may be made in open market, block or privately negotiated transactions, are not obligatory, and may be suspended or discontinued at any time. The press release says the increase follows an open letter to shareholders from the CEO and the market's response to it, but the filing gives no revenue, earnings or guidance figures.
Board authorized the increase on July 27, 2026, from $2.0 million to up to $3.0 million.
Repurchases may be made under Rule 10b-18, in open market, block or privately negotiated transactions, at the company's discretion.
The press release says the increase follows an open letter to shareholders from the CEO, but the 8-K is signed by CEO Hui Luo, while the press release names CEO Stephanie Luo.
Conagra Brands said Executive Vice President and Chief Operating Officer Thomas McGough notified the company on July 24, 2026 that he will retire no later than September 4, 2026. The company will eliminate the chief operating officer position when he leaves, so the filing reports a leadership change rather than a financial result.
Thomas McGough, EVP and Chief Operating Officer, gave notice of retirement on July 24, 2026
Retirement is effective no later than September 4, 2026
The chief operating officer position will be eliminated upon his retirement
Grace Therapeutics announced it received the FDA's official minutes from a Type A meeting on the April 23, 2026 Complete Response Letter for GTx-104. The company says the FDA cited facility-level cGMP issues at its contract manufacturer and additional leachables and excipient data, and it is adding a second, U.S.-based contract manufacturer as a backup route to resubmission. The filing gives no resubmission date, so the timing of a possible approval remains open.
FDA Type A meeting minutes received; CRL issued April 23, 2026 for GTx-104 new drug application
FDA did not identify clinical safety or efficacy deficiencies and did not request additional clinical data
Company is pursuing a dual-source manufacturing strategy with a second U.S.-based contract manufacturer; no single resubmission path has been designated
Corporate presentation updated July 28, 2026 to reflect the path to NDA resubmission
Hormel's board appointed John F. Ghingo, the company's current President and a board member, as President and Chief Executive Officer, effective October 26, 2026. Interim CEO Jeffrey M. Ettinger's service ends October 25, 2026, and he will remain on the board. The filing also sets Ghingo's new base salary at $1.28 million and a long-term incentive target of $6.8 million, which shareholders may watch as the company's leadership transition takes effect.
John F. Ghingo, age 53, appointed President and CEO effective October 26, 2026; he will also remain a board member.
Jeffrey M. Ettinger's interim CEO service concludes October 25, 2026; he will continue as a board member.
Ghingo's initial annual base salary is $1.28 million, with a short-term incentive target of 150% of base salary.
Long-term incentive target of $6.8 million per year, with about 50% in performance-based cash, 25% in stock options and 25% in restricted stock units.
ProMIS Neurosciences reported blinded six-month interim safety and biomarker data for PMN310 in its Phase 1b PRECISE-AD trial in early Alzheimer's disease, with no ARIA-E cases reported across 136 safety-evaluable patients. The trial remains blinded and ongoing, and the company said unblinded 12-month topline results, including efficacy data, are expected in the first quarter of 2027. The filing contains no financial results, so the update is clinical data that shareholders will weigh ahead of the readout.
No ARIA-E reported as of the July 22, 2026 data cutoff; 4.4% total ARIA, all mild and asymptomatic (ARIA-H only)
68.5% of patients had a plasma pTau217 decline from baseline and 62.5% had a CSF MTBR-tau243 decline; the company says allocations are still blinded
Unblinded 12-month topline results expected in Q1 2027, including efficacy data
Webinar held July 28, 2026 at 8:00 a.m. E.T. with KOLs Dr. Will Mantyh and Dr. Michael Weiner
Maison Solutions and its subsidiary AZLL signed a July 22, 2026 agreement to form Maison AI Limited, a Hong Kong company that will develop AI software for grocery retail and supply chains. AZLL would hold about 90.09% of the new company in exchange for contributing the Drem and WSYQR systems valued at $2,000,000, while two investors would pay $220,000 in cash for the remaining stakes.
AZLL would hold 200 of 222 shares (about 90.09%) after closing; Hangzhou Shengxianbao Technology and Yiwu Yanghan E-Commerce Firm would each pay $110,000 for 11 shares (about 4.96%).
The Software is valued at $2,000,000 and the company and its subsidiaries keep a perpetual, non-exclusive, royalty-free internal use license.
Cash payments are due in six monthly installments starting on or about September 1, 2026.
Closing is subject to conditions, and either side may terminate if it has not closed by March 31, 2027.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Briefs marked “Written later” were written in November 2026 for filings that were by then more than three weeks old, so months before mid-October 2026 hold a selection: every material 8-K of the past year for the 100 largest companies we cover and the last 15 important 8-Ks of every other one. Briefs the number check holds back are not shown or counted. Also: the last 45 days, briefs by company, A–Z and the live SEC filings wire.